1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SerpinA3 in the Early Recognition of Acute Kidney Injury to Chronic Kidney Disease (CKD) transition in the rat and its Potentiality in the Recognition of Patients with CKD

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recognizing patients at early phases of chronic kidney disease (CKD) is difficult, and it is even more challenging to predict acute kidney injury (AKI) and its transition to CKD. The gold standard to timely identify renal fibrosis is the kidney biopsy, an invasive procedure not usually performed for this purpose in clinical practice. SerpinA3 was identified by high-resolution-mass-spectrometry in urines from animals with CKD. An early and progressive elevation of urinary SerpinA3 (uSerpinA3) was observed during the AKI to CKD transition together with SerpinA3 relocation from the cytoplasm to the apical tubular membrane in the rat kidney. uSerpinA3/alpha-1-antichymotrypsin was significantly increased in patients with CKD secondary to focal and segmental glomerulosclerosis (FSGS), ANCA associated vasculitis (AAV) and proliferative class III and IV lupus nephritis (LN). uSerpinA3 levels were independently and positively associated with renal fibrosis. In patients with class V LN, uSerpinA3 levels were not different from healthy volunteers. uSerpinA3 was not found in patients with systemic inflammatory diseases without renal dysfunction. Our observations suggest that uSerpinA3 can detect renal fibrosis and inflammation, with a particular potential for the early detection of AKI to CKD transition and for the differentiation among lupus nephritis classes III/IV and V.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          The classification of glomerulonephritis in systemic lupus erythematosus revisited.

          The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving or =50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward.

            The 2012 KDIGO Guideline for CKD evaluation, classification, and management has updated the original 2002 KDOQI Guidelines, using newer data and addressing issues raised over the last decade concerning definitions and assessment. This review highlights the key aspects of the CKD guideline, and describes the rationale for specific wording and the scope of the document. A précis of key concepts in each of the five sections of the guideline is presented. The guideline document is intended for general practitioners and nephrologists, and covers CKD evaluation, classification, and management for both adults and children. Throughout the guideline, we have attempted to overtly address areas of controversy or non-consensus, international relevance, and impact on practice and public policy.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Surgery and portal hypertension.

                Bookmark

                Author and article information

                Contributors
                nab@biomedicas.unam.mx
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                17 July 2019
                17 July 2019
                2019
                : 9
                : 10350
                Affiliations
                [1 ]ISNI 0000 0001 2159 0001, GRID grid.9486.3, Molecular Physiology Unit, Instituto de Investigaciones Biomédicas, , Universidad Nacional Autónoma de México, ; Mexico City, Mexico
                [2 ]ISNI 0000 0001 0698 4037, GRID grid.416850.e, Department of Nephrology and Mineral Metabolism, , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, ; Mexico City, Mexico
                [3 ]ISNI 0000 0001 0698 4037, GRID grid.416850.e, Department of Experimental Pathology, , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, ; Mexico City, Mexico
                [4 ]ISNI 0000 0001 0698 4037, GRID grid.416850.e, Deparment of Internal Medicine, , Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, ; Mexico City, Mexico
                [5 ]ISNI 0000 0001 2203 4701, GRID grid.419886.a, Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, ; Monterrey, Nuevo León, Mexico
                Author information
                http://orcid.org/0000-0003-4062-9412
                http://orcid.org/0000-0002-3153-9151
                Article
                46601
                10.1038/s41598-019-46601-1
                6637202
                31316093
                c61b1d45-19bd-45cf-bb19-d90b513d0e38
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 24 October 2018
                : 29 June 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100003141, Consejo Nacional de Ciencia y Tecnología (National Council of Science and Technology, Mexico);
                Award ID: 235855, 235964, 272390, and A1-S-8715
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                kidney,chronic kidney disease
                Uncategorized
                kidney, chronic kidney disease

                Comments

                Comment on this article